Header Logo

Connection

Sunita Nathan to Retrospective Studies

Back to Details
This is a "connection" page, showing publications Sunita Nathan has written about Retrospective Studies.
Sunita Nathan
Connection Strength
0.616
Retrospective Studies
  1. Cardiovascular Risk Stratification of Patients Undergoing Hematopoietic Stem Cell Transplantation: The CARE-BMT Risk Score. J Am Heart Assoc. 2024 Jan 02; 13(1):e033599.
    View in: PubMed
    Score: 0.031
  2. Post-transplantation cyclophosphamide is associated with increased bacterial infections. Bone Marrow Transplant. 2024 Jan; 59(1):76-84.
    View in: PubMed
    Score: 0.030
  3. Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis. Haematologica. 2023 Jul 01; 108(7):1900-1908.
    View in: PubMed
    Score: 0.030
  4. Association of ABO mismatch with the outcomes of allogeneic hematopoietic cell transplantation for acute leukemia. Am J Hematol. 2023 04; 98(4):608-619.
    View in: PubMed
    Score: 0.029
  5. Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113 AML patients. Leukemia. 2023 05; 37(5):1006-1017.
    View in: PubMed
    Score: 0.028
  6. Myeloablative TBI is associated with increased risk of pulmonary GVHD in patients undergoing allogeneic hematopoietic stem cell transplant. Bone Marrow Transplant. 2022 10; 57(10):1632-1634.
    View in: PubMed
    Score: 0.028
  7. Transplantation provides superior survival high risk myeloid malignancies in older patients. Leuk Lymphoma. 2022 10; 63(10):2494-2498.
    View in: PubMed
    Score: 0.027
  8. Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors. JAMA Oncol. 2022 Mar 01; 8(3):404-411.
    View in: PubMed
    Score: 0.027
  9. Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. Blood Adv. 2022 01 11; 6(1):339-357.
    View in: PubMed
    Score: 0.027
  10. An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis. Bone Marrow Transplant. 2021 12; 56(12):3068-3077.
    View in: PubMed
    Score: 0.026
  11. Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults. Transplant Cell Ther. 2021 11; 27(11):923.e1-923.e12.
    View in: PubMed
    Score: 0.026
  12. Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2021 09; 56(9):2108-2117.
    View in: PubMed
    Score: 0.025
  13. Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. Leukemia. 2021 09; 35(9):2672-2683.
    View in: PubMed
    Score: 0.025
  14. Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study. Transplant Cell Ther. 2021 01; 27(1):68.e1-68.e9.
    View in: PubMed
    Score: 0.025
  15. Core-binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure. Int J Lab Hematol. 2021 02; 43(1):e19-e25.
    View in: PubMed
    Score: 0.024
  16. Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy. Oncologist. 2020 10; 25(10):878-885.
    View in: PubMed
    Score: 0.024
  17. Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapy. Br J Haematol. 2020 10; 191(1):44-51.
    View in: PubMed
    Score: 0.024
  18. Survival following allogeneic transplant in patients with myelofibrosis. Blood Adv. 2020 05 12; 4(9):1965-1973.
    View in: PubMed
    Score: 0.024
  19. Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma. Oncologist. 2020 06; 25(6):e993-e997.
    View in: PubMed
    Score: 0.024
  20. The Role of Donor Lymphocyte Infusion (DLI) in Post-Hematopoietic Cell Transplant (HCT) Relapse for Chronic Myeloid Leukemia (CML) in the Tyrosine Kinase Inhibitor (TKI) Era. Biol Blood Marrow Transplant. 2020 06; 26(6):1137-1143.
    View in: PubMed
    Score: 0.023
  21. Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure. Cancer. 2020 01 15; 126(2):293-303.
    View in: PubMed
    Score: 0.023
  22. Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. Haematologica. 2020 05; 105(5):1329-1338.
    View in: PubMed
    Score: 0.023
  23. Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. Blood Adv. 2019 06 25; 3(12):1826-1836.
    View in: PubMed
    Score: 0.022
  24. Impact of cachexia on outcomes in aggressive lymphomas. Ann Hematol. 2017 Jun; 96(6):951-956.
    View in: PubMed
    Score: 0.019
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.